The question isn’t if, but when, the next pandemic will hit. Research and observation have identified strong potential for the next pandemic-causing virus to come from one or more of five different virus families.
Tag: therapeutic antibodies
LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection
Inmazeb (REGN-EB3), developed by Regeneron, is a three-antibody cocktail designed to target the Ebola virus glycoprotein. The drug was first approved for clinical use in October 2020, but its exact mechanism of action has remained unclear.
Durable SARS-CoV-2 antibodies bind to two viral targets at once
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows how ideal antibodies against SARS-CoV-2 hit their marks. Now scientists are looking at how we might harness their power in new antibody therapeutics and even more effective COVID-19 vaccines.
NIH project seeks to improve cancer-fighting therapeutics
Scientists are examining how specialized immune cells called macrophages recognize and destroy target cells and why they sometimes do not.
Sanford Burnham Prebys announces research agreement with Lilly for COVID-19 antibody research
Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly’s next-generation anti-SARS-CoV-2 antibodies. These collaborative studies aim to build on Lilly’s current portfolio of neutralizing antibodies by exploring novel cocktails, half-life extension technologies and strategies to further enhance potency.